The potential role of perlecan domain V as novel therapy in vascular dementia

Metabolic Brain Disease

Volumn 30, Issue 1, 2015, Pages 1-5

  Marcelo, Aileen ^a   Bix, Gregory ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Domain V; Perlecan; Vascular dementia

Indexed keywords

AMYLOID BETA PROTEIN; ANGIOGENIC FACTOR; PERLECAN; PROTEOHEPARAN SULFATE;

ALZHEIMER DISEASE; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CAROTID ARTERY OBSTRUCTION; CEREBRAL AMYLOID ANGIOPATHY; CHEMISTRY; COMPLICATION; DEMENTIA, VASCULAR; DIABETIC ANGIOPATHIES; DISEASE MODEL; DRUG EFFECTS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; STROKE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CAROTID STENOSIS; CEREBRAL AMYLOID ANGIOPATHY; DEMENTIA, VASCULAR; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN STRUCTURE, TERTIARY; STROKE;

EID: 84939892349     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-014-9576-6     Document Type: Article

References (42)

1. Arikawa-Hirasawa E et al (1999) Perlecan is essential for cartilage and cephalic development. Nat Genet 23:354–358
2. 1 integrin. J Cell Biol 166(1):97–109
3. Bix G et al (2013) Perlecan domain V is neuroprotective and affords functional improvement in a photothrombotic stroke model in young and aged mice. Transl Stroke Res 5(5):515–23
4. Caplan L, Gomes J (2010) Binswanger disease—an update. J Neurol Sci 299:9–10
5. 1 and ERK-dependent signaling pathways. PLoS One 7(9):e45257
6. Costell M et al (1999) Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 147(5):1109–1122
7. Farach-Carson M, Carson D (2007) Perlecan: a multifunctional extracellular proteoglycan scaffold. Glycobiology 17(9):897–905
8. Ferrer I (2010) Cognitive impairment of vascular origin: Neuropathology of cognitive impairment of vascular origin. J Neurol Sci 299:139–149
9. Fujita Y et al (2010) Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke 41(12):2938–43
10. Fukuda S et al (2004) Focal cerebral ischemia induces active proteinases that degrade microvascular matrix. Stroke 35(4):998–1004
11. Ghiso J et al (2010) Cerebral amyloid angiopathy and Alzheimer’s disease. Hirosaki Igaku 61:S111–124
12. 1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): A dual receptor antagonism. J Biol Chem 286(29):25947–62
13. Harris J et al (2000) Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. PNAS 97(14):7754–59
14. Hooijmans C et al (2012) The effects of long-term omega-3 fatty acid supplementation of cognition and Alzheimer’s pathology in animals models of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 28(1):191–209
15. Iadecola C et al (2009) Threats to the mind: aging, amyloid, and hypertension. Stroke 40(3):S40–4
16. Iemolo F, et al (2009) Pathophysiology of vascular dementia. Immunity and Aging 6(13)
17. Iozzo R, San Antonio J (2001) Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108(3):349–355
18. Jellinger K (2013) Pathology and pathogenesis of vascular cognitive impairment—a critical update. Front Aging Neurosci 5:17
19. Jiang X et al (2004) Essential contribution of tumor-derived perlecan to epidermal tumor growth and angiogenesis. J Histochem Cytochem 52(12):1575–90
20. Kahle P et al (2012) Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue. Neuroreport 23(10):627–30
21. Kravitz E et al (2012) Cognitive decline and dementia in the oldest-old. Rambam Maimonides Med J 3(4):e0026
22. Lee B et al (2011) Perlecan domain v is neuroprotective and proangiogenic following ischemic stroke in rodents. J Clin Invest 121(8):3005–23
23. Lin B (2013) Encephalopathy: a vicious cascade following forebrain ischemia and hypoxia. Cent Nerv Syst Agents Med Chem 13:57–70
24. Maki T et al (2011) Angiogenic roles of adrenomedullin through vascular endothelial growth factor induction. Neuroreport 22(9):442–7
25. 1 integrin in angiogenic cerebral blood vessels of mice subject to hypobaric hypoxia. Mol Cell Neurosci 38(1):43–52
26. Mongiat M et al (2003) Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278(6):4238–49
27. Parham C et al (2014) Perlecan domain v inhibits amyloid-beta induced brain endothelial cell toxicity and restores angiogenic function. J Alzheimers Dis 38(2):415–23
28. Roberts J et al (2012) Perlecan and the blood-brain barrier: beneficial proteolysis? Front Pharmacol 3:155
29. Rocca W, Kokmen E (1999) Frequency and distribution of vascular dementia. Alzheimer Dis Assoc Disord 13(3):S9–14
30. Rodgers K et al (2007) Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome. Hum Mol Genet 16(5):515–28
31. Saini M, Bix G (2012) Oxygen-glucose deprivation (OGD) and interleukin-1 IL-differentially modulate cathepsin B/L mediated generation of neuroprotective perlecan LG3 by neurons. Brain Res 1438:65–74
32. Shee W, Ong W, Lim T (1998) Distribution of perlecan in mouse hippocampus following intracerebroventricular kainite injections. Brain Res 799(2):292–300
33. Shibata M et al (2004) White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 35(11):2598–603
34. Thal D et al (2012) Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol 47(11):816–24
35. Van Horssen J et al (2001) Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer’s disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol 102(6):604–16
36. Viswanathan A, Chabriat H (2006) Cerebral microhemorrhage. Stroke 37(2):550–5
37. Whitelock J et al (1996) The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271(17):10079–86
38. Wiesmann M et al (2013) Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab 33(11):1696–706
39. Willis C et al (2013) Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells. FEBS J 280(10):2271–84
40. Wright S et al (2012) Perlecan domain V inhibits α2 integin-mediated amyloid-β neurotoxicity. Neurobiol Aging 33(7):1379–88
41. Yamada K et al (2010) Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease. Brain Res 1352:176–86
42. Zhao G et al (2003) Temporal profile of tissue plasminogen activator (tPA) and inhibitor expression after transient focal cerebral ischemia. Neuroreport 14(13):1689–92